Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

A Anichini

Showing results (81-90 of 86) with videos related to

Pageof 9
Sort By:
You have reached the last page of results.This site can display upto 86 results.
Clinical Genetics|September 15, 2011
Allelic and phenotypic heterogeneity in 49 Italian patients with the muscle form of CPT-II deficiencyM Fanin, A Anichini, D Cassandrini, et al.
Cell Death & Disease|October 3, 2014
Synergistic anti-tumor activity and inhibition of angiogenesis by cotargeting of oncogenic and death receptor pathways in human melanomaG Grazia, C Vegetti, F Benigni, et al.
Cytokine & Growth Factor Reviews|October 15, 2017
Innovative Therapy, Monoclonal Antibodies and BeyondM Di Nicola, L Apetoh, M Bellone, et al.
Cancer Gene Therapy|January 23, 1999
Gene transfer into human dendritic antigen-presenting cells by vaccinia virus and adenovirus vectorsM Di Nicola, S Siena, M Bregni, et al.
Cytokine & Growth Factor Reviews|December 22, 2019
Anticancer innovative therapy: Highlights from the ninth annual meetingT Volpari, F De Santis, A P Bracken, et al.
ESMO Open|December 1, 2022
PEOPLE (NCT03447678), a first-line phase II pembrolizumab trial, in negative and low PD-L1 advanced NSCLC: clinical outcomes and association with circulating immune biomarkersG Lo Russo, F Sgambelluri, A Prelaj, et al.
Pageof 9

Showing results (81-90 of 86) with videos related to

Sort By:
Pageof 9
You have reached the last page of results.This site can display upto 86 results.
Clinical Genetics|September 15, 2011
Allelic and phenotypic heterogeneity in 49 Italian patients with the muscle form of CPT-II deficiencyM Fanin, A Anichini, D Cassandrini, et al.
Cell Death & Disease|October 3, 2014
Synergistic anti-tumor activity and inhibition of angiogenesis by cotargeting of oncogenic and death receptor pathways in human melanomaG Grazia, C Vegetti, F Benigni, et al.
Cytokine & Growth Factor Reviews|October 15, 2017
Innovative Therapy, Monoclonal Antibodies and BeyondM Di Nicola, L Apetoh, M Bellone, et al.
Cancer Gene Therapy|January 23, 1999
Gene transfer into human dendritic antigen-presenting cells by vaccinia virus and adenovirus vectorsM Di Nicola, S Siena, M Bregni, et al.
Cytokine & Growth Factor Reviews|December 22, 2019
Anticancer innovative therapy: Highlights from the ninth annual meetingT Volpari, F De Santis, A P Bracken, et al.
ESMO Open|December 1, 2022
PEOPLE (NCT03447678), a first-line phase II pembrolizumab trial, in negative and low PD-L1 advanced NSCLC: clinical outcomes and association with circulating immune biomarkersG Lo Russo, F Sgambelluri, A Prelaj, et al.
Pageof 9